MDGL SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 3, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 30, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 6, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 19, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 4, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 5, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Corporate Updates

Nov 3, 2026

8-K

Madrigal Pharmaceuticals Appoints Dr. John C. Reed to Board of Directors

Aug 12, 2026

8-K

Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Corporate Updates

Jul 30, 2026

8-K

Madrigal Pharmaceuticals Announces Stockholder Approval of 2026 Equity Plans and New Executive Compensation Arrangements

Jun 17, 2026

8-K

Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Pipeline Expansion

May 6, 2026

8-K

Madrigal Pharmaceuticals Reclassifies Board of Directors Membership

Apr 28, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

May 7, 2024

424B5

ATM | Offering amount: $300,000,000 | Amount sold to date: $225,100,000

May 7, 2024

424B5

750,000 Shares of Common Stock

Mar 20, 2024

424B5

Shares of Common Stock

Mar 18, 2024

424B5

1,248,098 Shares of Common Stock

Oct 2, 2023

424B5

Distributions on Our Common Stock

Sep 28, 2023

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jun 17, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Sep 11, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jun 20, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Oct 31, 2024

S-3ASR

SHELF

May 7, 2024

S-8

Registration

Sep 11, 2023

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 28, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 28, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2024

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13D/A

BAKER BROS. ADVISORS LP (Filed by)

Nov 6, 2026

BAKER JULIAN (Reporting)

Nov 6, 2026

Kelley Shannon T (Reporting)

Nov 6, 2026

144

Form 144 - Report of proposed sale of securities

Nov 6, 2026

144

Form 144 - Report of proposed sale of securities

Sep 28, 2026

Sibold William John (Reporting)

Sep 11, 2026

Other

TYPE

HEADLINE

FILED AT

LETTER

Form UPLOAD - SEC-generated letter

Jan 25, 2024

CORRESP

Form CORRESP - Correspondence

Jan 17, 2024

LETTER

Form UPLOAD - SEC-generated letter

Jan 3, 2024

CORRESP

Form CORRESP - Correspondence

Dec 14, 2023

CORRESP

Form CORRESP - Correspondence

Dec 8, 2023

LETTER

Form UPLOAD - SEC-generated letter

Nov 21, 2023

Madrigal Pharmaceuticals, Inc. MDGL · SEC Filings